Trial Profile
RACIN, A Phase I Study of the Combination of Nivolumab Associated With Low-dose Radiation, Aspirin/ Celecoxib, and Either Ipilimumab or Low-dose Cyclophosphamide, Followed by Nivolumab Maintenance, in Patients With Advanced, TIL-negative Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Aspirin
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms RACIN
- 18 Feb 2024 Status changed from active, no longer recruiting to completed.
- 13 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 16 Jul 2020 Planned End Date changed from 15 Mar 2023 to 30 Mar 2022.